- Home
- LPCN vs ANL Comparison
LPCN vs ANL Comparison
Compare LPCN & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPCN | ANL |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8M | 62.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | LPCN | ANL |
|---|---|---|
| Price | $8.83 | $9.50 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 109.4K | ★ 1.1M |
| Earning Date | 03-12-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,322,693.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.52 | $0.88 |
| 52 Week High | $12.37 | $12.09 |
Technical Indicators
Market Signals| Indicator | LPCN | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 52.92 | 77.72 |
| Support Level | $8.35 | $9.26 |
| Resistance Level | $9.15 | $10.77 |
| Average True Range (ATR) | 0.73 | 1.55 |
| MACD | -0.23 | 0.14 |
| Stochastic Oscillator | 33.29 | 77.24 |
Price Performance
Historical ComparisonAbout LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.